Cediranib

Phase 2Small molecule

Cediranib is a small molecule that works as a Vascular Endothelial Growth Factor Receptor Inhibitor; Platelet-Derived Growth Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor.[2] It is being investigated across 6 indications, with its most advanced program in Phase 2.[1]

Cediranib is one of 92 small molecule programs targeting Fallopian Tube Clear Cell Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fallopian Tube Clear Cell AdenocarcinomaActive, not recruiting

Colorectal NeoplasmsActive, not recruiting

Advanced Prostate AdenocarcinomaActive, not recruiting

Mismatch Repair Proficient Colorectal CancerActive, not recruiting

Solid TumorActive, not recruiting

Phase IIActive, not recruiting

Fallopian Tube Clear Cell AdenocarcinomaPreclinical

Active, not recruiting

Colorectal NeoplasmsPreclinical

Active, not recruiting

Advanced Prostate AdenocarcinomaPhase 2

Active, not recruiting

Mismatch Repair Proficient Colorectal CancerPhase 2

Active, not recruiting

Solid TumorPhase 1

Active, not recruiting

Phase IIPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Cediranib

AstraZeneca

Phase 2

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

3 3

Nubeqa

Bayer

Preclinical

2 4

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

2 5

Navmi

SSummit Therapeutics

Preclinical

1 6

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

Soc

Pfizer

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 10

Cadonilimab

SShanghai Pharmaceuticals Holding Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Solid Tumor

NCT00750841

Q1 2027

Phase 2Active, not recruiting

Mismatch Repair Proficient Colorectal Cancer

NCT03851614

PreclinicalActive, not recruiting

Fallopian Tube Clear Cell Adenocarcinoma

NCT02502266

Phase 1Active, not recruiting

Metastatic Melanoma

NCT01364051

Q2 2027

Phase 2Active, not recruiting

Advanced Prostate Adenocarcinoma

NCT02893917

Q3 2027

Phase 2Active, not recruiting

Recurrent Glioblastoma

NCT02974621

Clinical

Trials by Indication[1]

Ovarian Cancer6 trials

An RCT of Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer

Unknown status·MMedical Research Council·Phase 3·NCT00532194·486 enrolled

Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer

Completed·TThe Christie NHS Foundation Trust·Phase 1·NCT02855697·28 enrolled

Olaparib +/- Cediranib or Chemotherapy in Patients With Platinum-resistant Ovarian Cancer

Completed·UUniversity of Oxford·Phase 2·NCT03117933·139 enrolled

Show 3 more trials

A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer

Completed·UUniversity Health Network, Toronto·N/A·NCT02681237·34 enrolled

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Completed·UUniversity Health Network, Toronto·Phase 2·NCT02340611·4 enrolled

Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Unknown status·UUniversity College, London·Phase 3·NCT03278717·330 enrolled

Alveolar Soft Part Sarcoma2 trials

A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma (CASPS)

Unknown status·IInstitute of Cancer Research, United Kingdom·Phase 2·NCT01337401·36 enrolled

Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01391962·34 enrolled

Metastatic Colorectal Cancer2 trials

Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00399035·1,254 enrolled

First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX

Completed· AstraZeneca logo

AstraZeneca·Phase 2/3·NCT00384176·1,814 enrolled

Gastric Cancer1 trial

Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00960349·14 enrolled

Recurrent1 trial

Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib

Completed· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT03314740·123 enrolled

22 more indications

Chemotherapy1 trial

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00503204·20 enrolled

Glioblastoma1 trial

Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma

Completed· AstraZeneca logo

AstraZeneca·Phase 3·NCT00777153·423 enrolled

Renal Cell Cancer1 trial

WIRE - Novel Treatments in Renal Cell Cancer

Unknown status·CCCTU- Cancer Theme·Phase 2·NCT03741426·60 enrolled

Oral1 trial

Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™)

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00306891·60 enrolled

Advanced Solid Malignancies1 trial

A Study to Determine the Pharmacokinetics of Cediranib in Chinese Patients With Advanced Solid Malignancies

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00981721·20 enrolled

Radiotherapy1 trial

Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial

Terminated·TThe Christie NHS Foundation Trust·Phase 1·NCT01160926·31 enrolled

Endometrial Cancer1 trial

Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Unknown status·UUniversity of Manchester·Phase 2·NCT03570437·124 enrolled

Solid Tumours1 trial

Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours

Completed· AstraZeneca logo

AstraZeneca·Phase 1·NCT00750425·46 enrolled

Small Cell Lung Cancer1 trial

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT02899728·9 enrolled

Thyroid Cancer1 trial

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT01208051·127 enrolled

Renal Cell Carcinoma1 trial

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00423332·105 enrolled

Biliary Tract Cancer1 trial

Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers

Completed·UUniversity College, London·Phase 2/3·NCT00939848·124 enrolled

Phase II1 trial

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT03334617·528 enrolled

Advanced Gynecological Malignancies1 trial

AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies

Completed·—·Phase 1·NCT01065662·11 enrolled

Colorectal Neoplasms1 trial

Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody Durvalumab (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02484404·268 enrolled

Recurrent Glioblastoma1 trial

A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02974621·70 enrolled

Advanced Breast Carcinoma1 trial

Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast Cancer

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04090567·60 enrolled

Metastatic Melanoma1 trial

Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01364051·19 enrolled

Solid Tumor1 trial

A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTIN™), in Patients With Advanced Solid Tumours

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT00750841·64 enrolled

Mismatch Repair Proficient Colorectal Cancer1 trial

Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting·UUniversity Health Network, Toronto·Phase 2·NCT03851614·90 enrolled

Advanced Prostate Adenocarcinoma1 trial

A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT02893917·90 enrolled

Fallopian Tube Clear Cell Adenocarcinoma1 trial

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02502266·582 enrolled

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for Cediranib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cediranib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cediranib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Vascular Endothelial Growth Factor Receptor Inhibitor; Platelet-Derived Growth Factor Receptor Inhibitor; Stem Cell Growth Factor Receptor Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

Cediranib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Trials by Indication[1]

Ovarian Cancer6 trials

Alveolar Soft Part Sarcoma2 trials

Metastatic Colorectal Cancer2 trials

Gastric Cancer1 trial

Recurrent1 trial

Chemotherapy1 trial

Glioblastoma1 trial

Renal Cell Cancer1 trial

Oral1 trial

Advanced Solid Malignancies1 trial

Radiotherapy1 trial

Endometrial Cancer1 trial

Solid Tumours1 trial

Small Cell Lung Cancer1 trial

Thyroid Cancer1 trial

Renal Cell Carcinoma1 trial

Biliary Tract Cancer1 trial

Phase II1 trial

Advanced Gynecological Malignancies1 trial

Colorectal Neoplasms1 trial

Recurrent Glioblastoma1 trial

Advanced Breast Carcinoma1 trial

Metastatic Melanoma1 trial

Solid Tumor1 trial

Mismatch Repair Proficient Colorectal Cancer1 trial

Advanced Prostate Adenocarcinoma1 trial

Fallopian Tube Clear Cell Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News